Last updated 39 days ago

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

1000 patients around the world
Available in Chile, Mexico, United States, Brazil, Spain
AstraZeneca
1000Patients around the world
This study is for people with
Prostate cancer
Castration resistant prostate cancer
Requirements for the patient
To 130 Years
Male
Medical requirements
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy